Trials / Recruiting
RecruitingNCT07313579
Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
Observational Prospective Cohort Study on Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Ukrainian Society of Clinical Oncology · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.
Detailed description
Several recent studies showed that near-perfect curative-intent R0 surgical technique combined with systemic chemotherapy or even immunotherapy may not always be enough to eliminate microscopic deposits or eliminate peritoneal dissemination in locally advanced gastric cancer or low peritoneal cancer-index (PCI) tumors. The risk of peritoneal dissemination is especially high for T4 tumors, for those with cytologically positive peritoneal washings. Moreover, the risk of peritoneal relapse in low PCI tumors is remarkably high. Combination of surgery and intraperitoneal chemotherapy aims to minimise the risks of the aforementioned peritoneal progression. In the study investigators perform curative surgery followed by single dose of hyperthermic intraperitoneal chemotherapy (HIPEC).
Conditions
- Gastric Cancer (GC)
- HIPEC
- Peritoneal Metastases From Gastric Cancer
- Hyperthermic Intraperitoneal Chemoperfusion
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | curative-intent surgery + HIPEC | Participants enrolled in this study will undergo curative-intent gastrectomy for gastric cancer, immediately followed by Hyperthermic Intraperitoneal Chemotherapy (HIPEC) performed during the same operative session. Dosage of drugs: mitomycin C 15 mg/m2, cisplatin 75mg/m2. The procedure is conducted according to a standardized protocol in National Cancer Institute |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2030-12-01
- Completion
- 2035-12-01
- First posted
- 2026-01-02
- Last updated
- 2026-01-13
Locations
1 site across 1 country: Ukraine
Source: ClinicalTrials.gov record NCT07313579. Inclusion in this directory is not an endorsement.